Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 2

NCT06008288

A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harbor…

Patients with other advanced solid tumors (excluding NSCLC and CRC) who have progressed after prior systemic therapy or are intolerant and lack satisfactory alt…

China88 participantsStarted 2023-10-27

Treatment: JAB-21822

All recent trials (3 shown)

Not Yet RecruitingPhase 1/2

NCT07468071

Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agen…

The purpose of this study is to allow continued access to opnurasib (JDQ443) to participants who are benefitting from treatment with opnurasib as a single agent…

Location not specified40 participantsStarted 2026-06-15

Treatment: Opnurasib, TNO155

Not Yet RecruitingPhase 1/2

NCT06435455

GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors

This s a multi-center, open-label phase Ib/II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of GH21 combined with D-1553 in patient…

Location not specified126 participantsStarted 2024-07-01

Treatment: GH21, D-1553